JJ_Photo_Skyline of J&J building_JJ_1Star.JPG

Newsroom

The latest news, information and stories from Johnson & Johnson Innovative Medicine UK.

Press Releases

Sorry, I don't understand. Please try again

Filters

16 Results

Selected

Clear All

Immunology

TREMFYA® (guselkumab) subcutaneous (SC) induction data support the potential to become the first in its class to offer the option of both intravenous (IV) and SC induction therapy in ulcerative colitis

For UK medical and trade media only
For immediate release

February 21, 2025
Oncology

MHRA grants marketing authorisation for BALVERSA®▼ (erdafitinib) as monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC) harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting

For UK medical and pharmaceutical trade media only

November 6, 2024
Immunology

TREMFYA® (Guselkumab) is the first IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn’s disease

For UK medical and trade media only
For immediate release

October 29, 2024
Immunology

Johnson & Johnson transitions Remicade® (infliximab) and Simponi® (golimumab) for treatment of patients with Inflammatory Diseases

MEDIA STATEMENT FOR UK MEDICAL AND TRADE MEDIA ONLY
For Immediate Release

October 17, 2024
Haematology

NICE lifts restriction and recommends bispecific antibody TECVAYLI®▼ (teclistamab) for all eligible patients with relapsed and refractory multiple myeloma after three treatments

For UK medical, pharmaceutical trade and national health correspondents

October 10, 2024
Oncology

RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

For UK medical and trade media only
For immediate release

September 14, 2024
Oncology

RYBREVANT®▼ (amivantamab) plus lazertinib shows favourable overall survival trend in EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib

For UK medical and trade media only
For immediate release

September 11, 2024
Haematology

SMC accepts bispecific antibody TECVAYLI®▼ (teclistamab) for eligible patients with relapsed and refractory multiple myeloma

For UK national health correspondents, Scottish consumer media, and industry and medical media Under embargo until 09 September 2024 at 14.01 BST

September 9, 2024
Haematology

NICE issues draft guidance on bispecific antibody TECVAYLI®▼ (teclistamab) for eligible patients with relapsed and refractory multiple myeloma after three treatments

For UK medical, pharmaceutical trade and national health correspondents

July 19, 2024
Immunology

Guselkumab demonstrates superior efficacy versus Ustekinumab in first Phase 3 pooled data from two double-blind, placebo and active-controlled studies in Crohn’s disease

For UK medical and trade media only
For immediate release

May 21, 2024

CP-491724 | November 2024